Login to Your Account

Pharmacyclics' Stock Crushed After Failed Phase III Of Xcytrin

By Karen Pihl-Carey

Tuesday, December 20, 2005
A missed primary endpoint in a pivotal study of its lung cancer brain metastases drug, Xcytrin, sent Pharmacyclics Inc.'s stock plunging more than 64 percent Monday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription